IMM60 and Pembrolizumab in Melanoma and NSCLC

Summary

The goal of this clinical trial is to learn about IMM60 with or without pembrolizumab in participants with advanced melanoma or non-small cell lung cancer. There are two phases: * Phase 1: This phase is designed to learn about the safety of IMM60 with or without pembrolizumab and to find a safe dose to test in Phase 2. * Phase 2: This phase is designed to learn whether IMM60 + pembrolizumab improves progression-free survival at 12 months compared to pembrolizumab alone in participants with non-small cell lung cancer.

Timeline

Start

2023-11-15

Primary completion

2024-04-22

Completion

2024-04-22

Outcome

Outcome not reported

Stopped: “Prioritization of other pipeline assets. No safety or efficacy issues were observed.”

Drugs

Indications